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Introduction
Children represent approximately 15–20% of all systemic
lupus erythematosus (SLE) patients, and they usually have
a more severe disease at onset, higher rates of organ
involvement, and a more aggressive clinical course than
adults.
Aim
To analyze characteristics of the presenting and cumula-
tive clinical features, immunologic manifestations, dis-
ease activity and outcome of 62 Croatian children with
JSLE, followed between 1987 and 2007.
Results
There were 62 children, 52 girls and 10 boys, with the
mean age at disease onset (± SD) 12.9 ± 2.4 years. Fifty-
eight patients were followed for a mean period of 6.9 ± 5.3
yrs. The commonest presenting clinical features were con-
stitutional (fever, fatigue) (68%), arthralgias (56%), renal
involvement (53%) and malar rash (29%). Renal biopsy
revealed class IV lupus nephritis (LN) in 15 (45,5%), class
III LN in 9 (27,3%), class II LN in 5 (15,1%) and class V
LN in 4 (12,1%) cases. The patients presented signifi-
cantly altered laboratory parameters including deficiency
of complement C3 (93%) and C4 (95%), high ESR
(95%), cytopenia (73%) and positive anti-dsDNA
(100%). Only two patients had severe opportunistic infec-
tions: CNS nocardiosis and multifocal staphylococcal
osteomyelitis, both with good outcome. Due to clinical
presentation and laboratory data most patients were
treated with oral corticosteroids, followed by cyclophos-
phamide, pulse steroid, hydroxychloroquine and azathio-
prine. During the study period two patients died, one
because catastrophic antiphospholid syndrome, other
because of terminal renal failure.
Conclusion
There is no significant difference in clinical, immun-
opathological features and therapy regimens in our
patients compared to those in most paediatric SLE studies.
from 15th Paediatric Rheumatology European Society (PreS) Congress
London, UK. 14–17 September 2008
Published: 15 September 2008
Pediatric Rheumatology 2008, 6(Suppl 1):P243 doi:10.1186/1546-0096-6-S1-P243
<supplement> <title> <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p> </title> <editor>Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/PDF/1546-0096-6-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.ped-rheum.com/content/6/S1/P243
© 2008 Tambic Bukovac et al; licensee BioMed Central Ltd. 